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Abstract
Background: When to start or change antiretroviral 
treatment against HIV infection is of major importance. 
Patients’ readiness is considered a major factor influencing 
such treatment decisions, in particular because no objective, 
absolute time point when to start antiretroviral therapy 
exists. We aimed at evaluating patients’ readiness to start or 
change antiretroviral therapy (ART). 
Patients and Methods: HIV-infected patients starting 
or changing ART between July 2002 and February 2003, 
treating physicians and nurses participated in this 
prospective, observational multicenter study. We assessed 
shared decision-making including qualitative aspects, 
expected treatment decisions and treatment status after 3 
months.
Results: 75 patients were included. Of 34 patients for whom 
starting ART was considered, 27 (79%) indicated that they 
were willing to start treatment. After 3 months, 21 of 27 
(78%) actually started therapy, six did not. Patients with 
depression were less likely to be ready for ART (p < 0.05). 
Of 41 patients for whom changing ART was considered, 35 
(85%) indicated that they were willing to change treatment. 
Of the latter 35 patients, 33 (94%) finally changed ART 
within 3 months. Physicians and nurses were too optimistic 
in predicting the start or change of ART. The main reason 
to start or change ART was the sole recommendation of the 
physician (52% in those starting, 61% in those changing 
ART). Patients mainly judged the decision as shared and 
were very satisfied (71%) with the process. Qualitative 
findings revealed the importance of a dialectic decision-
making, described with two categories: “dealing with oneself 
and others
‚‚
 and “understanding and being understood.
‚‚
Conclusion: Patients mainly shared the decision made 
during consultation. Although physicians have an essential 
role concerning ART, patients, physicians, and nurses all 
contribute to the decision. Qualitative findings indicate the 
importance for health-care providers to include patients’ 
expertise and contributions.
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Introduction
Potent antiretroviral therapy (ART) has drastically re-
duced HIV-related morbidity and mortality [1–4]. How-
ever, HIV-infected individuals may face new difficulties, 
mainly related to long-term ART. The question “when to 
start” or “when to change ART” has become a major is-
sue for HIV-infected individuals and health-care provid-
ers. For instance, if providers prescribe ART only at an 
advanced disease stage, the risk for opportunistic infec-
tions and death increases [5]. The prescription of ART at 
an early stage of HIV infection with a low risk of clini-
cal progression, however, may lead to long-term side ef-
fects, possibly low adherence, development of resistance, 
and high costs. Treatment recommendations provide good 
assistance, however, as a clear CD4 T-cell threshold at 
which HIV-infected individuals benefit from initiation 
of therapy is missing,  individualization of treatment de-
cisions is needed [6]. For this reason, physicians and pa-
tients must integrate different aspects (e.g. the clinical and 
psychosocial situation, CD4 T-cell counts, and viral load) 
and thoroughly weigh risks and benefits of starting ART, 
in particular when CD4 T-cell counts are between 200/µl 
and 350/µl. Similarly, change of treatment is often a very 
complex decision. Importantly, the patients’ readiness to 
start or change ART is a strong argument to either initiate 
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or change ART. Although assumed to be highly important, 
the readiness of HIV-infected individuals to start or change 
therapy has been poorly investigated so far. We assume 
that readiness is the result of a complex treatment deci-
sion process. We adapted Llewellyn-Thomas’ [7] decision-
making framework to guide quantitative and qualitative 
research examining a patient’s readiness to start or change 
ART. Therefore, we explored the process of reaching a 
final treatment decision from both the patients’ as well as 
the health-care providers’ perspective including also the 
provider-patient relationship. 
Patients and Methods
HIV-Infected Individuals and Their Health-Care 
Providers
This study was performed at three clinics (Basel, Aarau, St.Gallen) 
participating in the Swiss HIV Cohort Study and one HIV center 
in Munich (Germany). The Swiss HIV Cohort Study represents 
a large-scale cohort of HIV-infected patients followed up every 3 
to 6 months with laboratory and clinical data recording. Between 
July 2002 and February 2003, all eligible, i.e. all HIV-infected 
patients with good knowledge of the German language were 
enrolled if a start or change of ART was considered. Physicians 
and nurses caring for a specific patient were also included in the 
study. Both of them were instructed for at least 60 min about the 
background, objective, methods and inclusion procedure before 
the study start. Later on the principal investigator assisted them in 
unclear situations. Informed consent was obtained from all study 
participants (patients, physicians, and nurses). Patient characteris-
tics assessed included gender, age, transmission mode, HIV stage, 
CD4 T-cell count, viral load, and duration of HIV infection at the 
time of inclusion. In addition, anxiety, depression scores and qual-
ity of life were elicited using the HADS-D (Hospital Anxiety and 
Depression Scale) and SF-8 questionnaires [8 –11]. The validated 
and standardized German version of the HADS-D and SF-8 were 
used. Important characteristics of physicians and nurses were also 
assessed (i.e. age, professional experience and the duration of the 
physician and nurse-patient relationship, respectively). Qualita-
tive in-depth interviews were conducted with 12 patients from the 
clinic in Basel to further explore their experience of ART deci-
sion-making and its influence by physicians and nurses. 
Exploring Treatment Decision-Making
We assessed expected treatment decisions immediately after 
consultation and the actual decision finally made. The issue of 
treatment decision may have been raised either by the treating 
physician or by the patient during the consultation. In this situa-
tion, physicians were instructed to ask patients to participate in 
this study. Patients with insufficient knowledge of the German 
language and patients who had already been enrolled in this study 
before were not eligible. In fact, the questionnaire was distributed 
by the physician in the following situations: i) surrogate markers 
which suggested that a start or change of therapy was indicated, ii) 
patients were suffering from a concomitant HIV-related disease, 
iii) patients reported significant side effects or iv) patient wished 
to start or change therapy even if there were no obvious reasons 
for a change as viewed by the physician. If any of these four situa-
tions were identified, the patient and the physician had to indicate 
after the consultation whether ART will be started or changed as 
agreed upon. Alternatively, the patient and physician could state 
that a patient was uncertain and therefore may start/change ART 
at a later time. This was done immediately after the consultation 
in a separate room for patients and physicians. The reason for a 
treatment decision from the patient’s perspective was elicited us-
ing a questionnaire. Patients had to state whether the treatment 
decision was made by them only, mainly by themselves, together 
with the physician, mainly by the physician or by the physician 
only [12]. 
Physicians and nurses stated whether they would expect the 
patient to start/change ART. If they considered a treatment start 
or change before the consultation (i.e. in 71%), they had to an-
swer an additional part of the questionnaire before the consulta-
tion with questions about their prediction. Finally, we assessed 
whether the patient actually started or changed therapy within 
3 months after the consultation when the questionnaire was dis-
tributed. Following this, patients were classified as either start-
ers, nonstarters, changers or non-changers. Patients without prior 
antiretroviral therapy or after treatment interruption were cat-
egorized as starters if they actually started ART within 3 months 
or as nonstarters if they did not. Patients already on ART were 
classified as changers if they actually changed the antiretroviral 
regimen within 3 months or as non-changers if they did not. 
Qualitative Analysis
The qualitative part followed a critical hermeneutic research de-
sign which emphasizes communication related to social, political, 
and cultural influence. A convenient patient sample of 12 patients 
was recruited from the participants of the quantitative study 
sample at Basel. Two to 3 months after a treatment decision was 
made during consultation, in-depth interviews were conducted 
with these patients. Six patients had considered starting and six 
changing therapy. All interviews were audiotaped and transcribed 
verbatim. Data were analyzed and interpreted using the approach 
of Diekelmann and Allen [13], i.e. texts were summarized and 
related themes and categories were identified. Categories were 
discussed with two independent experienced researchers and one 
study participant (an interviewed patient). Feedback from these 
discussions prompted analysis. During the final stage of analysis, 
categories that appeared in all texts were further refined. 
Statistics
The data of this study were analyzed in a descriptive way regard-
ing the decision-making behavior of patients. The differences 
in the HADS and SF-8 scores between the four patient groups 
were tested using one-way ANOVA. If the overall p-value was 
significant (p < 0.05), group comparisons were performed using 
Bonferroni correction.
Results
Patients, Physicians, and Nurses
A total of 81 HIV-infected patients were eligible for inclu-
sion. Of these, 75 patients were included in the study as 
shown in figure 1 as the entire data set, i.e. all questions 
answered, was not available in six patients. All but one pa-
tient were Swiss Germans or Germans. Of 34 patients with-
out ART (11 patients never had an ART before) for whom 
physicians and/or patients considered treatment, 27 (79%) 
indicated at the end of the consultation that they would 
start treatment and seven indicated that they would not. 
After 3 months, 21 (78%) patients actually started therapy 
and 13 did not. Importantly, six patients who decided they 
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would start therapy actually did not. Of the 41 patients in 
whom changing ART was considered, 35 (85%) patients in-
dicated that they would change treatment and six indicated 
that they would not. Of these 35 patients, 33 (94%) finally 
changed ART. In agreement with his physician one patient 
decided in the study consultation to interrupt treatment. 
This was considered a treatment change. Eight patients did 
not change ART within 3 months. Following this, 21 of 75 
patients were classified as starters, 13 as nonstarters, 33 as 
changers and eight as non-changers (Figure 1).
Patients’ characteristics including mean HADS-Anxi-
ety and Depression scores according to decision groups 
are shown in table 1. Nonstarters had a significantly higher 
depression score than starters (p < 0.05; mean difference in 
depression score: 5.63, 95% confidence interval: 1.78–9.48). 
Other group comparisons with respect to the HADS-Anxi-
ety and HADS-Depression score did not reach statistical 
significance. Mental and physical quality of life scores as 
measured by the SF-8 yielded values between 38.0 and 48.8 
but were not statistically significant (Table 1).
20 physicians and 12 nurses were study participants. 
Physicians were mostly men (60%) whereas nurses were 
mostly women (87%). Five physicians were between 20 
and 30 years old, eight between 30 and 40 and seven over 
40 years. Most nurses (n = 10) were over 40 years of age. In 
general, physicians and health-care workers were very ex-
perienced, i.e. physicians had a weighed average of 10 years 
experience and nurses 16 years, respectively. Experience 
in treating HIV-infected patients was also high (a weighed 
average of 7 years for physicians and 10 for nurses). Both, 
physicians and nurses cared for study patients for a simi-
lar period of time, i.e. 2.0 years and 2.4 years on average, 
respectively. In the study, physicians and nurses spent an 
average of 36 and 9 minutes with a patient, respectively.
Reasons for Treatment Decisions
Of the 75 patients, 66 (88%; n = 9 missing) provided in-
formation about their reason for the treatment decision 
(Table 2). Seven patients did not provide exact information 
on the treatment decision, i.e. they reported immediately 
after the consultation that they wished to wait for another 
3 months to decide (Table 2). The main reason to begin or 
change therapy (Table 2) was the sole recommendation of 
the physician (52% of starters and 61% of changers). All 
individuals except one indicated that they had received all 
the information needed to make a decision with respect 
to starting/changing ART. The physicians’ recommenda-
tion was based on CD4 T-cell counts, viral load and other 
parameters such as adverse events and laboratory side ef-
fects, i.e. the main reason from the physician’s perspective 
to start ART was a decrease in the patient’s CD4 T-cell 
count (52%). The main reasons for physicians to change 
therapy were adverse events (41%).
Prediction of Starting or Changing Therapy
Of 34 HIV-infected patients without ART, 27 decided to-
gether with the physician that they would start therapy. Im-
mediately after the consultation 26 patients predicted that 
they would start. Of these 26 patients, 21 actually started 
therapy (see Figure 1). Physicians and nurses predicted a 
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Eligible patients (n = 81)
Patients entered into
study (n = 75)
Starters and nonstarters (n = 34)
Potential starters (n = 27)a1 Potential nonstarters (n = 7)b1
Starters (n = 21)a2 Nonstarters (n = 13)b2 Changers (n = 33)c2 Non-changers (n = 8)d2
3 months later
Potential non-changers (n = 6)d1
Changers and non-changers (n = 41)
Patients who declined to
enter study (n = 6)
Potential changers (n = 35)c1
3 months later
Figure 1. Four groups of patients: starters, nonstarters and changers, non-changers (a1potential starters: 27 patients who decided to start ther-
apy. a2Starters: 21 [78%] patients started therapy within 3 months. b1Potential non-starters: seven patients who decided not to start therapy. 
b2Nonstarters: 13 patients who did not start within 3 months. c1Potential changers: 35 patients who decided to change therapy. c2changers: 33 
(94%) patients who changed within 3 months. d1Potential non-changers: six patients who decided not to change therapy. d2Non-changers: 
eight patients who did not change within 3 months).
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slightly higher rate of patients starting therapy, i.e. physi-
cians and nurses thought that 27, and 30 patients, respec-
tively, would start ART (Figure 2). Finally, 13 patients did 
not start therapy (Figure 2). Physicians predicted for seven 
patients that they would not start therapy. This prediction 
was two for nurses and patients, respectively. With respect 
to changing ART, the predicted treatment decisions were 
similar for the three study groups (Figure 2).
Shared Decision-Making
Patients were asked (n = 72, three missing) how they 
would describe the decision-making process that led to the 
treatment decision. This was done immediately after hav-
ing seen the physician. As shown in figure 3, more than 
50% of starters (n = 12, 57%), changers (n = 17, 53%), 
and non-changers (n = 4, 57%) perceived the treatment 
decision as shared  “we decided together”. Nonstarters and 
non-changers more often stated “I decided mainly by my-
self.” Importantly, none of the patients reported that the 
physician decided alone. These results are in concordance 
with the finding that patients preferred a shared approach. 
Starters as well as changers and non-changers preferred 
to decide together with their physician (47%, 65%, 88%, 
respectively). Furthermore, 71% of patients were very sat-
isfied with the overall setting and content of the consulta-
tion and an additional 25% were satisfied. Only one patient 
answered being moderately satisfied. None of the patients 
reported being not or not at all satisfied.
Qualitative Aspects
Qualitative findings reflect the experiences of four women 
and eight men during the decision-making process. Two 
main aspects evolved, i.e. a) dealing with oneself and 
others and b) understanding and being understood. 
Dealing with Oneself and Others. Patients experienced the 
entire decision process as highly distressing and even though 
a decision was made at the end, it was never perceived as 
final. They emphasized the time they needed for their inner 
dialogue and for discussions with others before making a 
 Starters             Nonstarters       Changers           Non-changers
No. of patients   21    13      33                            8
Gender (% male) 19 (90%)  6 (46%) 27 (82%)    8 (100%)
Age at sampling time (mean, SD) 41 (28–60)   41 (28–65)   46 (26–76)    39 (31–48)
Transmission category
Men having sex with men 11 (52%)  3 (23%) 21 (64%)   3 (38%)
Heterosexual contacts   5 (24%) 1 (8%)  6 (18%)   1 (12%)
Injecting drug users   5 (24%)  6 (46%)  4 (12%)  4 (50%)
Injecting drug users/sexual cont. 0 (0%)  2 (15%) 0 (0%) 0 (0%)
Unknown 0 (0%) 1 (8%) 2 (6%) 0 (0%)
HIV stage (CDC)
A   8 (38%)  6 (46%)     9 (27.3%)   2 (25%)
B   8 (38%)  4 (31%)    13 (39.4%)      3 (37.5%)
C   5 (24%)  3 (23%)   11 (33.3%)      3 (37.5%)
HIV infection
Duration of HIV infection 6.5 (± 5.2) 12.8 (± 4.6) 9.3 (± 4.3) 10.6 (± 5.0)
at sampling time, years (mean, SD)
CD4 cell count 380 237 442 438
(mean, median, SD; cells/µl) (369 ± 212) 235 ± 177) (378 ± 289) (391 ± 311)
Viral load, plasma 5.05 4.20 2.69   3.72
(mean, median, SD; log 10 c/ml) (5.46 ± 0.83) (4.06 ± 1.15) (2.25 ± 1.42) (3.93 ± 1.24)
Anxiety and depression
HADS-Anxietya 5.85 8.8 4.9 6.1
HADS-Depressionb 3.2*  8.8* 3.6 4.4
Quality of life
SF-8 MCSc (mean, SD) 4.6 (± 9.5) 3.8 (± 12.7) 47.9 (± 8.6) 47.6 (± 7.0)
SF-8 PCSd (mean, SD) 48.8 (± 12.0) 44.1 (± 9.5) 48.2 (± 10.1) 47.6 (± 11.2)
a Hospital Anxiety and Depression Scale; score: no anxiety < 8, questionable 8–11, anxiety disorder > 11; b Hospital Anxiety and Depression 
Scale; score: no depression < 8, questionable 8–11, depressive disorder > 11; c mental component summary; average of 
United States’ population = 50; d physical component summary; average of United States’ population = 50; * p < 0.05
Table 1
Characteristics of HIV-infected individuals (n = 75) and main outcomes in questionnaires concerning anxiety, depression, and quality of life.
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decision. All interviewed patients worried about the side 
effects of a (new) treatment, especially the visible ones 
such as lipodystrophy.  Patients balanced pros and cons of 
a treatment start or change very carefully. A 38-year-old 
man reported: “One goes back and forth and feels torn. 
Lipodystrophy affects my legs and this is disturbing but 
I can deal with it at the moment. It may be that a new 
medication helps – but one does not really know how it 
turns out.” 
Dialogues with others included reports about discus-
sions with family members and friends. Patients told us that 
discussions with other HIV-infected people and health-
care providers were most important. Information gathered 
through different media was also a key factor. Physicians 
and nurses were an important source of information, espe-
cially for persons with little illness experience. More expe-
rienced patients emphasized the different sources of infor-
mation they used: “The information from friends and from 
the internet cannot be replaced by physicians, because the 
consultations are very limited and one is alone afterwards 
anyway.”  
Understanding and Being Understood. As a result of the 
diverse dialogues, patients were able to understand their 
situation and felt understood by others. Discussions with 
health-care providers for instance helped to overcome wor-
ries and provided security. Some patients, however, did not 
feel really understood. Their inner dialogue, e.g. how they 
thought about the virus or how they felt related to the ill-
ness, was not concordant with the information they received 
from others. These patients explained that they could not 
understand the explanations of professionals and felt under 
pressure to take a decision they were not yet sure about. As 
a result, they expressed feelings of distress and anxiety. 
Discussion
In this prospective study we explored the readiness to start 
or change ART in 75 HIV-infected individuals. We have 
shown that a) patients mainly complied with the decision 
made during the consultation and that physicians, nurses 
and to a lesser degree patients were too optimistic in pre-
dicting the start or change of ART, b) the main reasons to 
start or change ART were the physician’s recommenda-
tion, and the reflection in dialogues that patients empha-
sized, c) patients mostly perceived the process as “shared 
decision-making”, and d) depression was associated with a 
lower readiness to start or change therapy. 
 Starters             Nonstarters       Changers           Non-changers
No. of patients   21    13      33                            8
To start/change
Physician told me 11 (52.0%) 3 (23.0%) 20 (61.0%) 2 (25.0%)
Decrease in CD4 1  1 1 0
Increase in VL 2  0 0 0
I feel bad 2  0 4 0
Other reasonb 2  0 3 0
Not to start/change
I feel healthy 1 1  0 1
I fear side effects 0 0 0 1
I fear toxic effects for the future (e.g. lipodystrophy) 0 1  0 0
Other reasonc 0 0 0 1
To wait (another 3 months)
I agree to start/change when next HIV 
parameters remain unfavorable 1 1 1 2 (25.0%)
I need time to think about the situation 1 0 0 1
Other reason 0 0 1 0
Missing 0  6 (46.0%) 3 0
a Patients were allowed to choose only the most appropriate answer; b answers like: “I started/ changed ART because I know other HIV-in-
fected individuals who started or changed therapy” or “a person in relationship recommended to start or change therapy” were not reported. 
Other reasons to start ART were “I want a baby” or “I want a non-detectable viral load to decrease the risk to infect my partner”, other rea-
sons to change were “I want a simplified therapy” and “I want a non-detectable viral load to decrease the risk to infect my partner“
c Other possible answers like: “I will wait for a better therapy” or “the proposed therapy is too complicated” or “former HIV-parameters do 
not indicate that I have to start/change therapy” or “I would like a second opinion” or “I know other HIV-infected individuals, who had 
bad experiences with the medication” or “a person in a close relationship recommended not to start/change therapy” were not reported. 
One patient reported in the section “other reason”: “I have to travel abroad for a certain time and therefore I will not change therapy.” 
Percentages only given when > 20%.
Table 2
Main reason for patients to start (not to start)/ change (not to change) a therapya.
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Patients mainly complied with the decision made dur-
ing the consultation. Of 27 patients who decided to start 
therapy, 78% actually started ART. Of 35 patients who 
decided to change therapy, 94% actually did. These re-
sults show a high concordance between planned and real 
treatment procedures. This indicates that both patients 
and physicians agreed on the treatment decision to a large 
extent and that the physician-patient communication was 
“successful”. Nevertheless, physicians and nurses were too 
optimistic in predicting the start or change of ART. Recent 
studies indicate that the providers’ prediction and percep-
tion of readiness and adherence to therapy may play an 
important role in prescribing ART. Bogart et al. [14, 15] 
showed that most physicians treating HIV-infected indi-
viduals weighed patient’s prior history of poor adherence 
and socio-demographic factors against initiating ART. 
McNaghten et al. [16] found that ART prescription differs 
by gender, race, exposure mode, alcoholism, and provider 
type. Earlier, we demonstrated that the physician’s percep-
tion of a patient not complying with treatment was the main 
reason for not prescribing ART [17]. However, physicians’ 
perception may not be a reliable basis for treatment deci-
sions because of their questionable prediction of patients’ 
adherence [18–22]. 
The main reason to start or change antiretroviral ther-
apy was the physician’s recommendation. This was the case 
in 52% of the starter group and 61% of the changer group. 
As we asked patients to indicate only the most important 
reason, this probably led to an underestimation of reasons 
that were not dominant. However, this may have allowed 
a better discrimination for reasons that were more influ-
ential in deriving a decision. The notion that the physician 
is a very important partner for judging the appropriate-
ness of treatment decisions is supported by a recent study. 
Meystre et al. [23] reported that 42% of a cohort of 830 
patients expressed that the physician’s advice was one of 
the main reasons to accept ART. The qualitative catego-
ries of “dealing with oneself and others” shed light on the 
patients’ expertise related to daily life and personal illness 
management. Also, the category of “understanding and 
being understood” indicates some dissatisfaction with the 
decision-making process and reveals how distressing such 
a situation might be. It also shows that patients’ treatment 
decisions are dependent upon patients’ perceptions of un-
derstanding the situation and feeling understood by health-
care providers and support persons [24].
In our study almost all (97%) HIV-infected individuals 
reported that they had received all the information needed 
to decide whether to start or change ART. HIV-infected 
individuals mostly perceived the process as “shared deci-
sion-making.” This confirms previous findings of Marelich 
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Figure 2. Prediction of starting (a) and changing (b) antiretroviral 
therapy compared to those who really started or changed therapy. 
Figure 2a: black bars depict “start”, white bars “no start”, grey bars 
answers such as: “I do not know” or “I/ she/ he will start soon, i.e. 
within the next 3 months”. Figure 2b: black bars depict “change”, 
white bars “no change”, and grey bars answers such as: “I do not 
know” or “I/she/he will start soon, i.e. within the next 3 months.”
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Figure 3. HIV-infected individuals’ judgement about involvement in 
the treatment decision. Black bars depict “starters”, bars with 
diagonals “nonstarters”, grey bars “changers”, and white bars “non-
changers.”
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et al. [25] who found that HIV-infected individuals were 
generally actively involved in the decision-making process. 
In this latter study a passive attitude of the patient was only 
found immediately after HIV infection was diagnosed. An 
active role was also found by others [26]. In addition, our 
study shows that physicians and nurses are important part-
ners and therefore strongly influence the readiness of HIV-
infected patients for therapy. This is also supported by our 
finding that the physician’s recommendation was the main 
reason to start or change ART, stressing the importance 
of the provider-patient communication and relationship. 
Along these lines, 71% of patients were “very satisfied” 
with the decision-making process. It may be that these 
encouraging results are partly based on the great experi-
ence of physicians and nurses. In addition, the more critical 
qualitative data emphasize the importance of communica-
tion skills of physicians and nurses with patients [27].
A higher depression score was associated with lower 
readiness to start antiretroviral therapy. Despite the low 
number of patients this result was significant. A meta-
analysis of ten studies, including a total of 2,596 persons, 
by Ciesla et al. [28] provides strong evidence that HIV in-
fection is associated with greater risk for major depressive 
disorders. Similarly, we found high scores for anxiety and 
depression in a large survey within the Swiss HIV Cohort 
Study even in asymptomatic patients with good surrogate 
markers [29]. Consequently, depression has to be consid-
ered when starting or changing ART.
Our study has limitations. First, the number of patients 
included in this study is rather low, e.g. gender differences 
could not be analyzed. However, the design to investigate 
patients, physicians, and nurses was to analyze prospec-
tively detailed quantitative as well as qualitative aspects. 
Hence, our results may give important insights for decision-
making with respect to ART. Second, the follow-up period 
for evaluating whether the treatment decision was actually 
realized was only 3 months. A longer period of time may 
have affected the number of patients in the different de-
cision groups as, e.g. some additional patients may have 
started therapy. However, we sought to determine whether 
the decision taken during consultation was actually real-
ized within a short period of time, because otherwise the 
decision-making process may have been influenced by new 
aspects. Finally, the decision-making process may have 
been influenced by the communication skills of health pro-
fessionals as well as by difficulties of health professionals in 
assessing the patient’s readiness. However, most physicians 
and nurses had substantial professional experience in treat-
ing HIV-infected patients and their communication skills 
should be reflected by their level of experience. Further-
more, the results were very similar across the four included 
study sites (data not shown) and overall patient satisfac-
tion was high arguing against an unbalanced influence of 
health-care providers. Nevertheless, we cannot exclude a 
selection bias of our study population. It is possible that the 
positive perception of the decision-making process and the 
high satisfaction rate were partly due to a selection of pa-
tients who were a priori satisfied with the involved centers. 
Yet, this reflects real conditions.  
The recommendation of a doctor seems very impor-
tant; however, shared decision-making turned out to be 
a crucial support for all the involved persons. Also, our 
qualitative data indicate that treatment decisions are a dy-
namic process strongly linked to personal experiences. As 
therapeutic options become more and more individualized, 
further qualitative research is needed to improve the un-
derstanding of the treatment decision process.
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